Fingerprint
Dive into the research topics of 'Alirocumab and cardiovascular outcomes after acute coronary syndrome'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Alirocumab and cardiovascular outcomes after acute coronary syndrome
ODYSSEY OUTCOMES Committees and Investigators
- University of Colorado Anschutz Medical Campus
- University of Alberta
- University of Toronto
- Université Paris Cité
- Imperial College London
- SUNY Downstate Health Sciences University
- Harvard University
- University of Alabama at Birmingham
- Instituto Cardiovascular de Rosario
- Sanofi-Aventis
- Stanford University
- Duke University
- Leiden University
- University of North Carolina at Chapel Hill
- Regeneron Pharmaceuticals, Inc.
- Auckland District Health Board
- Goethe University Frankfurt
- Flinders University
- Landeskrankenhaus Feldkirch
- Vorarlberg Inst Vaskulare Forsch VIVIT
- KU Leuven
- University of Sarajevo
- Universidade Federal de São Paulo
- MHAT Natl Cardiol Hosp EAD
- Universidad de Chile
- Peking University
- Fdn Oftalmol Santander FOSCAL
- University of Zagreb
- Na Homolce Hospital
- Nemocnice Na Homolce
- Aarhus University
- SA Pohja Eesti Reg Haigla
- HUS Helsinki University Hospital
- INSERM UMR-S1140
- Chapidze Emergency Cardiol Ctr
- RWTH Aachen University
- University of Ioannina
- Unidad Diagnost Cardiol
- The University of Hong Kong
- Magyar Honvedseg Egeszsegugyi Kozpont
- St. John's National Academy of Health Sciences
- Ben-Gurion University of the Negev
- University of Ferrara
- Kyoto University
- Seoul National University
- Chang Gung Memorial Hospital
Research output: Contribution to journal › Journal Article › peer-review
2653
Scopus
citations